Larimar Therapeutics, Inc.
General ticker "LRMR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $225.1M (TTM average)
Larimar Therapeutics, Inc. follows the US Stock Market performance with the rate: 39.1%.
Estimated limits based on current volatility of 4.9%: low 3.25$, high 3.59$
Factors to consider:
- Total employees count: 42 (+61.5%) as of 2023
- Top business risk factors: Regulatory and compliance, Labor/talent shortage/retention, Geopolitical risks, Market competition, Supply chain disruptions
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.00$, 5.89$]
- 2025-12-31 to 2026-12-31 estimated range: [1.48$, 4.35$]
Financial Metrics affecting the LRMR estimates:
- Positive: with PPE of -3.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -29.18 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 85.81 > 63.39
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term LRMR quotes
Long-term LRMR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $36.53MM | $41.76MM | $90.89MM |
| Operating Income | $-36.53MM | $-41.76MM | $-90.89MM |
| Non-Operating Income | $1.17MM | $4.81MM | $10.29MM |
| R&D Expense | $24.25MM | $27.67MM | $73.28MM |
| Income(Loss) | $-35.35MM | $-36.95MM | $-80.60MM |
| Profit(Loss)* | $-35.35MM | $-36.95MM | $-80.60MM |
| Stockholders Equity | $110.90MM | $81.72MM | $171.81MM |
| Assets | $126.41MM | $95.94MM | $200.22MM |
| Operating Cash Flow | $-27.57MM | $-33.46MM | $-70.76MM |
| Capital expenditure | $0.10MM | $0.16MM | $0.52MM |
| Investing Cash Flow | $-90.96MM | $33.35MM | $-85.39MM |
| Financing Cash Flow | $75.26MM | $0.03MM | $161.88MM |
| Earnings Per Share** | $-1.37 | $-0.84 | $-1.32 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.